Veradigm Inc (MDRX)

$4.80 0.00 (N/A)
Market Cap 519.67M
Revenue (ttm) 588.02M
Net Income (ttm) -86.46M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -14.70%
Debt to Equity Ratio 0.20
Volume 15,900
Avg Vol 88,096
Day's Range N/A - N/A
Shares Out 108.27M
Stochastic %K 19%
Beta 0.77
Analysts Sell
Price Target $7.17

Company Profile

Veradigm Inc., a healthcare technology company, provides information technology solutions to healthcare providers, payers, and biopharma markets in the United States and internationally. The company offers solutions to healthcare providers, comprising practice management software, AI patient scheduling software, and electronic statements and payments, and payerpath clearinghouse; revenue cycle services and coding services; electronic health records solutions, which include eprescribe with EPCS,...

Industry: Health Information Services
Sector: Healthcare
Phone: 800 334 8534
Address:
222 Merchandise Mart Plaza, Suite 2024, Chicago, United States
LordWellesley
LordWellesley Nov. 4 at 9:19 AM
It looks like Oracle Cerner $ORCL is taking over Veradigm $MDRX from the inside with the new CEO. chief innovation officer and now the HR lead coming out of that direction.
0 · Reply
sirspanky
sirspanky Oct. 30 at 5:14 PM
$HCTI pullback to ~$2.X.74 after tapping $3.X = microcap mechanics more than thesis change. $3.X round-number/profit-taking + sell algos. S-3/resale + $3.X warrant overhang = supply into strength. Thin book magnifies moves. Still like the setup: sub-1× EV/S on ~$12–14M vs health-IT micros ~2–3.5×. Catalysts ahead: stockholder vote/S-3 effectiveness (cleanup) + HIS/SaaS integration sharpening the cloud→data→AI story (CloudEz/DataEz/Readabl.AI). Watching $2.X.60–$2.X.70 as near support; re-test of $3.X if volume rotates back. Context: $MDRX $CPSI $GEHC. Not advice.
0 · Reply
sirspanky
sirspanky Oct. 29 at 6:05 PM
$HCTI popped to $3.06 and the setup still looks early. Why bullish: • Re-rate room: On ~$12–14M rev, HCTI was trading well sub-1× EV/S. Typical health-IT micros often fetch ~2–3.5×. A simple move to the low end of that band points to mid-$4S–$6S equity value (before any upside from integration/execution). • Catalysts: S-3/overhang mechanics are now better understood, shareholder approval path is clear, and the HIS/SaaS additions + CloudEz/DataEz/Readabl.AI sharpen the cloud→data→AI platform story. Peer context: If you track $MDRX and $CPSI on provider IT—or premium vertical SaaS like $VEEV—HCTI is the under-followed version earlier on the curve with headroom to normalize multiples. Not advice—just sharing the thesis & math. 🚀
0 · Reply
sirspanky
sirspanky Oct. 27 at 7:57 PM
$HCTI New coverage just hit on $HCTI — calling out a differentiated cloud→data→AI stack, re-accelerating revs, and a path to margin expansion (init PT ~$6). At ~$2.X.6–2.7, HCTI still screens sub-1× EV/S on ~$12–14M rev while health-IT micros often fetch ~2–3.5×. Catalysts ahead: S-3/overhang cleanup, stockholder vote, plus integration of the HIS/SaaS assets. If you watch vertical health IT like $MDRX and $CPSI—or premium vertical SaaS like $VEEV—this is the under-the-radar version earlier on the curve. Not advice; do your DD. 🚀 Source: Zacks Small Cap Research initiation (10/27/25). https://finance.yahoo.com/news/hcti-initiating-coverage-differentiated-information-092900656.html
0 · Reply
sirspanky
sirspanky Oct. 24 at 7:02 PM
$HCTI POWER HOUR 👀 $HCTI @ ~$2.X.69(sub-$2.X.70) – sleeper set-up • Undervalued: ~$12–14M rev vs sub-1× EV/Sales today, while provider/health-IT peers often fetch ~2–3.5× (and leaders like $VEEV command premium multiples). Priced like a contractor, building a cloud → data → AI platform (CloudEz / DataEz / Readabl.AI). • Catalysts + cash runway: Stockholder call/earnings + S-3 on file to clean up the ~$3 overhang. If new $3 warrants get exercised, that’s ~$4.3M of fresh fuel to scale the growing hospital/health-system business (100+ sites served) and the new HIS/SaaS push. Why talk now? Turbulent tape sends money to hospital-centric efficiency plays. If you like the theme in $MDRX, $GEHC, or premium SaaS like $VEEV, keep an eye on this under-the-radar version with leverage to upside. Tape’s thin into the close—small bids can matter. Do your own DD. 🚀
0 · Reply
sirspanky
sirspanky Oct. 24 at 6:18 PM
$HCTI eading into the stockholders call & earnings with quiet-but-big setup vibes. Why we’re excited: Undervalued: On ~$12–14M rev, HCTI still screens sub-1× EV/Sales while Health-IT names often fetch ~2–3.5×. You’re paying “services” multiples for a cloud→data→AI platform (CloudEz / DataEz / Readabl.ai). Clean-up + cash option: Stockholder vote + S-3 effectiveness should clear the ~$3 overhang. If $3 warrants get exercised, that’s fresh cash to extend runway just as the HIS/SaaS LOI plugs in and expands front-end CX/agent workflows. What I’ll listen for: bookings mix, integration milestones, margin path, and any color on timing for the vote/S-3. Context tickers (not comps, just the lane): $VEEV (vertical SaaS premium), $MDRX (provider IT), $GEHC (digitized care). Sleeper micro-cap, efficient-care tailwind, and catalysts lining up. Not advice—watch the tape.
0 · Reply
LordWellesley
LordWellesley Sep. 30 at 8:22 PM
Looks like Veradigm $MDRX sold its stake in #Holmusk. (Cash inflow from portfolio activities). Any views?
0 · Reply
LordWellesley
LordWellesley Sep. 30 at 8:14 PM
$MDRX Any views on the press release?
0 · Reply
LordWellesley
LordWellesley Sep. 23 at 10:38 PM
$MDRX a business update on Sep 30th when Q3 is not yet tallied ?
1 · Reply
LordWellesley
LordWellesley Aug. 28 at 5:51 AM
What an unloved, hidden gem is Veradigm $MDRX. Of course, it is taking them forever to reset their finances and the resulting delisting to the OTC sinbin doesn’t help. However, despite soaring accounting/consulting costs related to the reset they are generating 100 mln plus in free cashflow. Under a new CEO they are quietly building a strong position at the cutting edge of (performance based) medical practice efficiency, RWD generation and RWE analysis for the pharma world. By springtime the admin worries will finally be over and some simple arithmetic (120 mln fcf x 15 divided by 110 mln shares) will triple the current price. $SPY
0 · Reply
Latest News on MDRX
No data available.
LordWellesley
LordWellesley Nov. 4 at 9:19 AM
It looks like Oracle Cerner $ORCL is taking over Veradigm $MDRX from the inside with the new CEO. chief innovation officer and now the HR lead coming out of that direction.
0 · Reply
sirspanky
sirspanky Oct. 30 at 5:14 PM
$HCTI pullback to ~$2.X.74 after tapping $3.X = microcap mechanics more than thesis change. $3.X round-number/profit-taking + sell algos. S-3/resale + $3.X warrant overhang = supply into strength. Thin book magnifies moves. Still like the setup: sub-1× EV/S on ~$12–14M vs health-IT micros ~2–3.5×. Catalysts ahead: stockholder vote/S-3 effectiveness (cleanup) + HIS/SaaS integration sharpening the cloud→data→AI story (CloudEz/DataEz/Readabl.AI). Watching $2.X.60–$2.X.70 as near support; re-test of $3.X if volume rotates back. Context: $MDRX $CPSI $GEHC. Not advice.
0 · Reply
sirspanky
sirspanky Oct. 29 at 6:05 PM
$HCTI popped to $3.06 and the setup still looks early. Why bullish: • Re-rate room: On ~$12–14M rev, HCTI was trading well sub-1× EV/S. Typical health-IT micros often fetch ~2–3.5×. A simple move to the low end of that band points to mid-$4S–$6S equity value (before any upside from integration/execution). • Catalysts: S-3/overhang mechanics are now better understood, shareholder approval path is clear, and the HIS/SaaS additions + CloudEz/DataEz/Readabl.AI sharpen the cloud→data→AI platform story. Peer context: If you track $MDRX and $CPSI on provider IT—or premium vertical SaaS like $VEEV—HCTI is the under-followed version earlier on the curve with headroom to normalize multiples. Not advice—just sharing the thesis & math. 🚀
0 · Reply
sirspanky
sirspanky Oct. 27 at 7:57 PM
$HCTI New coverage just hit on $HCTI — calling out a differentiated cloud→data→AI stack, re-accelerating revs, and a path to margin expansion (init PT ~$6). At ~$2.X.6–2.7, HCTI still screens sub-1× EV/S on ~$12–14M rev while health-IT micros often fetch ~2–3.5×. Catalysts ahead: S-3/overhang cleanup, stockholder vote, plus integration of the HIS/SaaS assets. If you watch vertical health IT like $MDRX and $CPSI—or premium vertical SaaS like $VEEV—this is the under-the-radar version earlier on the curve. Not advice; do your DD. 🚀 Source: Zacks Small Cap Research initiation (10/27/25). https://finance.yahoo.com/news/hcti-initiating-coverage-differentiated-information-092900656.html
0 · Reply
sirspanky
sirspanky Oct. 24 at 7:02 PM
$HCTI POWER HOUR 👀 $HCTI @ ~$2.X.69(sub-$2.X.70) – sleeper set-up • Undervalued: ~$12–14M rev vs sub-1× EV/Sales today, while provider/health-IT peers often fetch ~2–3.5× (and leaders like $VEEV command premium multiples). Priced like a contractor, building a cloud → data → AI platform (CloudEz / DataEz / Readabl.AI). • Catalysts + cash runway: Stockholder call/earnings + S-3 on file to clean up the ~$3 overhang. If new $3 warrants get exercised, that’s ~$4.3M of fresh fuel to scale the growing hospital/health-system business (100+ sites served) and the new HIS/SaaS push. Why talk now? Turbulent tape sends money to hospital-centric efficiency plays. If you like the theme in $MDRX, $GEHC, or premium SaaS like $VEEV, keep an eye on this under-the-radar version with leverage to upside. Tape’s thin into the close—small bids can matter. Do your own DD. 🚀
0 · Reply
sirspanky
sirspanky Oct. 24 at 6:18 PM
$HCTI eading into the stockholders call & earnings with quiet-but-big setup vibes. Why we’re excited: Undervalued: On ~$12–14M rev, HCTI still screens sub-1× EV/Sales while Health-IT names often fetch ~2–3.5×. You’re paying “services” multiples for a cloud→data→AI platform (CloudEz / DataEz / Readabl.ai). Clean-up + cash option: Stockholder vote + S-3 effectiveness should clear the ~$3 overhang. If $3 warrants get exercised, that’s fresh cash to extend runway just as the HIS/SaaS LOI plugs in and expands front-end CX/agent workflows. What I’ll listen for: bookings mix, integration milestones, margin path, and any color on timing for the vote/S-3. Context tickers (not comps, just the lane): $VEEV (vertical SaaS premium), $MDRX (provider IT), $GEHC (digitized care). Sleeper micro-cap, efficient-care tailwind, and catalysts lining up. Not advice—watch the tape.
0 · Reply
LordWellesley
LordWellesley Sep. 30 at 8:22 PM
Looks like Veradigm $MDRX sold its stake in #Holmusk. (Cash inflow from portfolio activities). Any views?
0 · Reply
LordWellesley
LordWellesley Sep. 30 at 8:14 PM
$MDRX Any views on the press release?
0 · Reply
LordWellesley
LordWellesley Sep. 23 at 10:38 PM
$MDRX a business update on Sep 30th when Q3 is not yet tallied ?
1 · Reply
LordWellesley
LordWellesley Aug. 28 at 5:51 AM
What an unloved, hidden gem is Veradigm $MDRX. Of course, it is taking them forever to reset their finances and the resulting delisting to the OTC sinbin doesn’t help. However, despite soaring accounting/consulting costs related to the reset they are generating 100 mln plus in free cashflow. Under a new CEO they are quietly building a strong position at the cutting edge of (performance based) medical practice efficiency, RWD generation and RWE analysis for the pharma world. By springtime the admin worries will finally be over and some simple arithmetic (120 mln fcf x 15 divided by 110 mln shares) will triple the current price. $SPY
0 · Reply
Whiskey1679
Whiskey1679 Aug. 23 at 7:59 PM
Whiskey's Penny Stock Picks out Monday morning! High Volume Stocks this past week: $XTPT $MDRX $BMPA $SDRC $QSEP
0 · Reply
LordWellesley
LordWellesley Aug. 18 at 9:03 PM
Veradigm $MDRX appoints Don Trigg as its new ceo. A healthcare venture cap background and ex Cerner (Oracle) in short: the plot thickens… $ORCL https://investor.veradigm.com/news-releases/news-release-details/veradigm-appoints-don-trigg-chief-executive-officer Veradigm Appoints Don Trigg as Chief Executive Officer | Veradigm Inc.
0 · Reply
LordWellesley
LordWellesley Jul. 23 at 4:10 AM
Experts call for action to fulfil the potential of real-world data in pharma research $IQV $ICLR $MDRX https://becarispublishing.com/digital-content/blog-post/experts-call-action-fulfil-potential-real-world-data-research
0 · Reply
LordWellesley
LordWellesley Jul. 17 at 10:22 AM
$MDRX quietly building up a wide moat.
0 · Reply
LordWellesley
LordWellesley Jun. 19 at 2:11 PM
$MDRX Veradigm to Release Business Update June 23rd and Host Investor Call June 24th.
0 · Reply
DonCorleone77
DonCorleone77 May. 12 at 12:16 PM
$MDRX Veradigm advances GLP-1 real-world evidence generation with AI Veradigm announced an advancement in the use of artificial intelligence to scale the generation of real-world evidence for GLP-1 receptor agonists, including semaglutide and tirzepatide. By applying AI to electronic health record deidentified data within the Veradigm Network, researchers can now surface rich, contextual insights-such as side effects, discontinuation reasons, and social determinants of health-that traditionally required intensive manual curation.
0 · Reply
LordWellesley
LordWellesley Apr. 22 at 11:28 PM
Veradigm $MDRX interim CEO Tom Langan is leaving the company with immediate effect. Does anyone know why? The press release only describes his severance package.
0 · Reply
LordWellesley
LordWellesley Apr. 18 at 1:44 AM
Veradigm $MDRX has fired @GrantThorntonUS for failing to spot sizeable accounting mistakes in the period 2019-2024. Leading to the current delisting. No doubt a hefty claim is in the making. @BDO_USA will take over.
0 · Reply
LordWellesley
LordWellesley Apr. 4 at 7:08 AM
Veradigm $MDRX interim CEO Tom Langan now owns 329,000 shares. Come on Tom make something happen (and yourself rich 🤑) !! https://investor.veradigm.com/static-files/f88e9901-c761-4557-9e35-623d411c39a4
0 · Reply
LordWellesley
LordWellesley Mar. 14 at 7:14 AM
Finally some movement re the updated Veradigm results and outlook but the message is vague. No mention even of the ‘22 etc. repairs. What’s brewing? Let’s find out. https://investor.veradigm.com/node/25121/pdf $MDRX
0 · Reply
IOMASS
IOMASS Mar. 13 at 4:21 PM
$MDRX Something/someone out there pushing some volume - a number of block trades - maybe near-term earnings release (finally) - we'll see...
1 · Reply
LordWellesley
LordWellesley Feb. 25 at 11:00 AM
Don’t fall into this greed trap Veradigm. https://www.linkedin.com/posts/activity-7299925500821389312-5C7x?utm_medium=ios_app&rcm=ACoAAAITHYMBRtFnjNkFrVUgIpka1TkAdtue6Oc&utm_source=social_share_send&utm_campaign=copy_link $MDRX
0 · Reply